NCT01916967View on ClinicalTrials.gov

An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)

PHASE3CompletedINTERVENTIONAL
Enrollment

239

Participants

Timeline

Start Date

August 27, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

March 13, 2014

Conditions
Urticaria
Interventions
DRUG

Desloratadine

Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks

DRUG

Placebo

Placebo tablets, given orally, once daily in the evening for 2 weeks

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT01916967 - An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201) | Biotech Hunter | Biotech Hunter